ストックスクリーナーアプリを入手
0.2801
10.71%
0.0271
アフターアワーズ：
.57
0.2899
+103.50%
前日終値:
$0.253
開ける：
$0.2469
24時間の取引高:
61.93M
Relative Volume:
26.15
時価総額：
$4.30M
収益：
$4.71M
当期純損益:
$-11.79M
株価収益率:
-0.0836
EPS:
-3.3492
ネットキャッシュフロー:
$-9.72M
1週間 パフォーマンス:
+7.07%
1か月 パフォーマンス:
-1.37%
6か月 パフォーマンス:
-54.06%
1年 パフォーマンス:
-86.34%
1日の値動き範囲:
$0.2469
$0.2944
1週間の範囲:
$0.24
$0.2944
52週間の値動き範囲:
$0.23
$2.75
Ensysce Biosciences Inc Stock (ENSC) Company Profile
名前
Ensysce Biosciences Inc
セクター
電話
(858) 263-4196
住所
7946 IVANHOE AVENUE, LA JOLLA
Compare ENSC vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ENSC
Ensysce Biosciences Inc
|
0.2801 | 4.02M | 4.71M | -11.79M | -9.72M | -3.3492 |
VRTX
Vertex Pharmaceuticals Inc
|
470.72 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
759.24 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
830.79 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
182.45 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
313.77 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ensysce Biosciences Inc (ENSC) 最新ニュース
Ensysce Biosciences Inc (ENSC) Cash Flow - TradingKey
ENSC|Ensysce Biosciences Inc|Price:0.255|Chg%:-0.006 - TradingKey
TradingKey - TradingKey
Ensysce Biosciences Inc (ENSC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Ensysce Biosciences Inc (ENSC) Institutional Confidence - TradingKey
Ensysce Biosciences Inc (ENSC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Ensysce Biosciences Inc (ENSC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ensysce Biosciences Inc (ENSC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ENSC News | ENSYSCE BIOSCIENCES INC (NASDAQ:ENSC) - ChartMill
Ensysce Biosciences COO Jeffrey Millard resigns effective July 10, 2026 - TradingView
COO Jeffrey Millard exits Ensysce Biosciences (Nasdaq: ENSC) July 10 - Stock Titan
Ensysce Biosciences, Inc. Announces Resignation of Jeffrey Millard as Chief Operating Officer, Effective July 10, 2026 - marketscreener.com
Ensysce receives $5.3M NIDA award for opioid overdose therapy By Investing.com - Investing.com Nigeria
Ensysce receives $5.3M NIDA award for opioid overdose therapy - Investing.com
Ensysce Biosciences Receives Final $5.3 Million NIDA Funding Installment for PF614-MPAR Development - Yahoo Finance
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant - Weatherford Democrat
Federal funds back Ensysce opioid technology designed to limit overdose - Stock Titan
Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth - Yahoo Finance Singapore
Ensysce Biosciences (ENSC) Edges Higher: Key Support Holds as Volume Picks UpProfitability Factor - dars.gov.et
Ensysce Biosciences, Inc. Financial Disclosures & SEC Filings - TradingView
12 Health Care Stocks Moving In Thursday's After-Market SessionSeer (NASDAQ:SEER), Universe Pharmaceut - Benzinga
Price to sales forward of Ensysce Biosciences, Inc. – NASDAQ:ENSC - TradingView
Enterprise value to revenue forward of Ensysce Biosciences, Inc. – NASDAQ:ENSC - TradingView
Price to earnings forward of Ensysce Biosciences, Inc. – NASDAQ:ENSC - TradingView
Price to book forward of Ensysce Biosciences, Inc. – NASDAQ:ENSC - TradingView
Enterprise value to EBITDA forward of Ensysce Biosciences, Inc. – NASDAQ:ENSC - TradingView
[EFFECT] Ensysce Biosciences, Inc. SEC Filing - Stock Titan
Ensysce initiates final stage of opioid overdose protection study By Investing.com - Investing.com Nigeria
Ensysce Biosciences enrolls first patient in final stage of PF614-MPAR-102 study - grafa.com
Ensysce initiates final stage of opioid overdose protection study - Investing.com
Ensysce starts final PF614-MPAR study stage for overdose-protection opioid - Stock Titan
Ensysce Biosciences, Inc. Actuals & Estimates (NASDAQ:ENSC) - TradingView
ENSC Should I Buy - Intellectia AI
Ensysce Biosciences Inc (ENSC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ENSYSCE BIOSCIENCES INC (ENSC) Stock Chart - ChartMill
Ensysce Biosciences Inc (ENSC) Valuation: PE, PB & Fair Value Analysis - TradingKey
Ensysce Biosciences Inc (ENSC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Ensysce Biosciences Slips 3.94% as Stock Tests Key Support at $0.23New Listing Stocks - newsline.com
ENSC Q1 2026 Earnings: Narrowing Losses Signal Progress Amid Market VolatilityEarnings Acceleration Picks - lwvtexas.org
Ensysce Biosciences Files for Sale of 1.3 Million Shares - Moomoo
Ensysce Biosciences (NASDAQ: ENSC) registers up to 1.3M shares for resale - Stock Titan
ENSC Q1 2026 Earnings: Narrower-Than-Expected Loss Despite No RevenueEarnings Whisper Number - The Legal Advocate
ENSC Q1 2026 Earnings: Narrower-than-expected loss boosts sharesMargin Guidance - newsline.com
Ensysce Biosciences (ENSC) Drops 3% as Stock Nears Support at $0.28MA Crossover - The Legal Advocate
Ensysce Biosciences (ENSC) Declines Further, Tests Key Support Near $0.29Diamond Pattern - Newser
ENSCEnsysce Biosciences Inc Stock Price and Quote - Finviz
Ensysce Faces New Nasdaq Issue as Deadline Nears - Bez Kabli
ENSC Q1 2026 Earnings: Narrower-than-expected Net Loss as EPS Beats EstimatesSegment Revenue Breakdown - The Legal Advocate
Ensysce Biosciences, Inc. Files Form 8-K: Company Details, Nasdaq Listing, and Compliance Update - Minichart
Ensysce Biosciences receives Nasdaq notice for non-compliance with equity rule - Investing.com
Ensysce Biosciences Inc (ENSC) 財務データ
収益
当期純利益
現金流量
EPS
1.84%
0.91%
大文字化:
|
ボリューム (24 時間):